- Home
- MODD vs KPTI Comparison
MODD vs KPTI Comparison
Compare MODD & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- KPTI
- Stock Information
- Founded
- MODD 1998
- KPTI 2008
- Country
- MODD United States
- KPTI United States
- Employees
- MODD N/A
- KPTI N/A
- Industry
- MODD Industrial Specialties
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- KPTI Health Care
- Exchange
- MODD Nasdaq
- KPTI Nasdaq
- Market Cap
- MODD 35.5M
- KPTI 33.6M
- IPO Year
- MODD N/A
- KPTI 2013
- Fundamental
- Price
- MODD $0.89
- KPTI $4.95
- Analyst Decision
- MODD
- KPTI Strong Buy
- Analyst Count
- MODD 0
- KPTI 5
- Target Price
- MODD N/A
- KPTI $61.00
- AVG Volume (30 Days)
- MODD 155.4K
- KPTI 161.4K
- Earning Date
- MODD 02-13-2025
- KPTI 05-07-2025
- Dividend Yield
- MODD N/A
- KPTI N/A
- EPS Growth
- MODD N/A
- KPTI N/A
- EPS
- MODD N/A
- KPTI N/A
- Revenue
- MODD N/A
- KPTI $145,237,000.00
- Revenue This Year
- MODD N/A
- KPTI $4.87
- Revenue Next Year
- MODD N/A
- KPTI $16.29
- P/E Ratio
- MODD N/A
- KPTI N/A
- Revenue Growth
- MODD N/A
- KPTI N/A
- 52 Week Low
- MODD $0.68
- KPTI $3.51
- 52 Week High
- MODD $2.65
- KPTI $21.30
- Technical
- Relative Strength Index (RSI)
- MODD 43.99
- KPTI 48.29
- Support Level
- MODD $0.79
- KPTI $3.83
- Resistance Level
- MODD $0.95
- KPTI $4.36
- Average True Range (ATR)
- MODD 0.10
- KPTI 0.43
- MACD
- MODD -0.01
- KPTI 0.22
- Stochastic Oscillator
- MODD 28.42
- KPTI 91.72
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.